Medication info
Olomax Tablet 40/5/10 mg (Olmesartan medoxomil, Amlodipine, Rosuvastatin)

Olomax Tablet 40/5/10 mg (Olmesartan medoxomil, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.95mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Daewong Pharmaceutical Co., Ltd.
Appearance
Light pink round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202000708 · Approved 2020.02.06 · Insurance code 641607190

Summary

Main use
Treatment of hypertension and dyslipidemia; reduction of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine should be administered once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the olmesartan medoxomil/amlodipine combination and rosuvastatin. For patients taking olmesartan medoxomil/amlodipine and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Olmesartan medoxomil/amlodipine combination Before administering this medicine, it is recommended that the doses of the individual components (olmesartan medoxomil or amlodipine) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 40/10 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. (olmesartan medoxomil/amlodipine) 20/5 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg or amlodipine 5 mg monotherapy. 40/5 mg: For patients whose blood pressure is not adequately controlled with 20/5 mg. 40/10 mg: For patients whose blood pressure is not adequately controlled with 40/5 mg. Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose with adequate monitoring of their condition. Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See the section “Do not administer to the following patients” under Precautions for Use.) Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored more closely and more frequently. Rosuvastatin Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose for adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 mg daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients.

Ingredients

Manufacturer
Daewong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; reduction of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take both Olmesartan medoxomil/Amlodipine combination and Rosuvastatin. The combination of Olmesartan medoxomil and Amlodipine is effective in treating essential hypertension when it is difficult to control blood pressure alone. Rosuvastatin helps treat hypercholesterolemia and mixed hyperlipidemia that cannot be controlled by diet and exercise and is also used for patients with homozygous familial hypercholesterolemia. Additionally, this medication plays a significant role in lowering total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis, and reducing the risk of cardiovascular disease. Rosuvastatin also reduces the risk of complications after stroke, myocardial infarction, and vascular revascularization. Therefore, this medication is used for the management of hypertension and hyperlipidemia and for improving cardiovascular disease risk.

How to take

Adult dose

This medicine should be administered once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the olmesartan medoxomil/amlodipine combination and rosuvastatin. For patients taking olmesartan medoxomil/amlodipine and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Olmesartan medoxomil/amlodipine combination Before administering this medicine, it is recommended that the doses of the individual components (olmesartan medoxomil or amlodipine) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 40/10 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. (olmesartan medoxomil/amlodipine) 20/5 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg or amlodipine 5 mg monotherapy. 40/5 mg: For patients whose blood pressure is not adequately controlled with 20/5 mg. 40/10 mg: For patients whose blood pressure is not adequately controlled with 40/5 mg. Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose with adequate monitoring of their condition. Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See the section “Do not administer to the following patients” under Precautions for Use.) Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored more closely and more frequently. Rosuvastatin Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose for adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 mg daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to the fetus and newborn, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients allergic to the active ingredients of this medication or similar medications, pregnant or breastfeeding women, patients with severely impaired liver or kidney function, and patients with specific heart diseases should not take this medication. Patients who are deficient in fluids or salts may experience hypotension when taking this medication, thus their condition should be carefully monitored, and appropriate measures taken if hypotension occurs. Patients with heart valve disease should be especially cautious, as rapid vasodilation can lead to hypotension. Patients with coronary artery disease or heart failure may experience worsened cardiac conditions when taking this medication, so it should be taken carefully under a doctor’s instruction. Patients with impaired renal function or kidney transplant patients should regularly check their kidney function and serum electrolyte levels before and during treatment with this medication. Patients with liver dysfunction may be affected by the metabolism and action of this medication, necessitating dose adjustment and monitoring. This medication may increase serum potassium levels, so patients at risk for hyperkalemia should periodically check their serum potassium levels. If symptoms of muscle pain or weakness occur, inform a doctor immediately and undergo necessary tests, and discontinue the medication if severe. This medication may cause side effects such as liver function abnormalities, gastrointestinal disorders, headache, dizziness, and edema in some patients, so consult healthcare professionals if symptoms persist or worsen. There may be interactions when used in combination with other medications, so if other drugs are being taken, it is important to inform healthcare professionals, especially when used with potassium-sparing diuretics, lithium, or non-steroidal anti-inflammatory drugs. Taking this medication with grapefruit juice may increase its serum concentration, so it is recommended to avoid grapefruit juice consumption. Special care is not specifically required during driving or operating machinery, but caution should be exercised if symptoms such as dizziness occur.

Side effects

  • Palpitations
  • upper abdominal pain
  • vomiting
  • weakness
  • peripheral edema
  • bacterial pneumonia
  • subarachnoid hemorrhage
  • elevated ALT
  • elevated AST
  • hypoglycemia
Show 131 more
  • dizziness
  • headache
  • hematuria
  • allergic rhinitis
  • cough
  • wet cough
  • rash
  • arterial embolism
  • drug hypersensitivity reaction
  • hyperkalemia
  • decreased libido
  • orthostatic hypotension
  • drowsiness
  • sensory disturbance
  • diminished sensation
  • syncope
  • vertigo
  • chest palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • erectile dysfunction
  • edema
  • dependent edema
  • fatigue
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • multiple organ dysfunction syndrome
  • viral pneumonia
  • benign neoplasm
  • malignant neoplasm
  • neoplasm of uncertain behavior
  • adrenal adenoma
  • sinus tachycardia
  • oropharyngeal discomfort
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • urticaria
  • autoimmune hepatitis
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • chest palpitations
  • dizziness
  • headache
  • drowsiness
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • myalgia
  • myopathy
  • immune-mediated necrotizing myopathy
  • lupus-like syndrome
  • muscle rupture
  • arthralgia
  • immune-mediated necrotizing myopathy
  • hematuria
  • edema
  • depression
  • sleep disorders
  • interstitial lung disease
  • sexual dysfunction
  • gynecomastia
  • fatal liver failure
  • non-fatal liver failure
  • cognitive impairment
  • memory decline
  • forgetfulness
  • amnesia
  • memory disorders
  • confusion
  • severe myasthenia gravis
  • ocular myasthenia
  • headache
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • weight loss
  • heartburn
  • gastroenteritis
  • cholelithiasis
  • herpes zoster
  • diplopia
  • female breast neoplasm
  • insomnia
  • cerebral infarction exacerbation
  • gum bleeding
  • constipation
  • numbness
  • sensory disturbance
  • chest discomfort
  • nausea
  • abdominal pain
  • appetite loss
  • abdominal distension
  • abnormal liver function tests
  • syncope
  • muscle cramps
  • gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. Storing it this way can help maintain the efficacy and safety of the medication.

Appearance and packaging

Appearance

Light pink round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.